This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on elevated ASC levels in older adults (>60 years) who were cognitively normal at baseline but demonstrated cognitive decline one year later (NI) compared to ASC levels in those who: 1. Were cognitively normal at both baseline and 1 year later (NN), and 2. Were cognitively impaired at both baseline and one year later (II) Inflammasome-induced neuroinflammation has been associated with early stag ...